TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED has completed patient enrollment for the SAFFRON Phase III trial, which investigates the combination of ORPATHYS® and TAGRISSO® as a treatment for NSCLC patients with MET overexpression after progression on TAGRISSO®. This trial could potentially lead to global regulatory filings if results are favorable, marking a significant step in offering a chemotherapy-free treatment option for lung cancer patients.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited operates in the pharmaceutical industry, focusing on the development and commercialization of targeted therapies for cancer treatment. The company collaborates with AstraZeneca to develop ORPATHYS®, a selective MET tyrosine kinase inhibitor, and TAGRISSO®, an EGFR tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) patients.
Average Trading Volume: 9,903,414
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$20.72B
See more insights into 0013 stock on TipRanks’ Stock Analysis page.